CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway

Molecular Carcinogenesis

Volumn 54, Issue S1, 2015, Pages E35-E44

  Lin, Fu ^a   Chengyao, Xie ^a   Qingchang, Li ^a   Qianze, Dong ^a   Enhua, Wang ^a   Yan, Wang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CRKL; ERK; Invasion; MMP9; NSCLC

Indexed keywords

CRK LIKE PROTEIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR PROTEIN; PRIMER DNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CANCER CELL; CELL INVASION; CELL INVASION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LUNG CANCER; LUNG CANCER CELL LINE; LYMPH NODE METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ENZYME ACTIVATION; ENZYMOLOGY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84931569046     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22148     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
3. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; 27:3277-3283.
4. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105:31-52.
5. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-572.
6. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood 1994; 84:1731-1736.
7. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001; 20:6348-6371.
8. Fidler IJ, Kripke ML. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet 2003; 34:23, author reply 25.
9. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 1993; 8:2469-2474.
10. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
11. Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem 1996; 271:23255-23261.
12. ten Hoeve J, Kaartinen V, Fioretos T, et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res 1994; 54:2563-2567.
13. Feller SM, Posern G, Voss J, et al. Physiological signals and oncogenesis mediated through Crk family adapter proteins. J Cell Physiol 1998; 177:535-552.
14. Singer CF, Hudelist G, Lamm W, et al. Active (p)CrkL is overexpressed in human malignancies: Potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep 2006; 15:353-359.
15. Kim YH, Kwei KA, Girard L, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 29:1421-1430.
16. Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1:608-625.
17. Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poorprognosis and cell proliferation in non-small cell lung. Mol Carcinog 2013; 52:890-899.
18. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998; 10:667-671.
19. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991; 51:5054s-5059s.
20. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
21. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010; 141:52-67.
22. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5:149-153.
23. Shiraga M, Yano S, Yamamoto A, et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res 2002; 62:5967-5973.
24. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6:3944-3948.
25. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20:1311-1316.
26. Baruch RR, Melinscak HLo J, Liu Y, Yeung O, Hurta RA. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int 2001; 25:411-420.
27. Munoz-Najar UM, Neurath KM, Vumbaca F. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006; 25:2379-2392.
28. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 1999; 10:407-416.
29. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-947.
30. Webb CP, Van Aelst L, Wigler MH, Vande Woude GF. Signaling pathways in Ras-mediated tumorigenicity, metastasis. Proc Natl Acad Sci USA 1998; 95:8773-8778.
31. Arai A, Kanda E, Nosaka Y, Miyasaka N, Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem 2001; 276:33282-33290.
32. Arai A, Nosaka Y, Kohsaka H, Miyasaka N, Miura O. CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. Blood 1999; 93:3713-3722.
33. Ihle JN. Cytokine receptor signalling. Nature 1995; 377:591-594.
34. Koval AP, Karas M, Zick Y, LeRoith D. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction. J Biol Chem 1998; 273:14780-14787.
35. Nosaka Y, Arai A, Miyasaka N, Miura O. CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3. J Biol Chem 1999; 274:30154-30162.